 |
Prismocitrate 18 |
|---|---|
| Trade Name | |
| Orphan Indication | Use as replacement solution (includes regional anticoagulation of the extracorporeal circuit) in patients undergoing continuous renal replacement therapy (CRRT) |
| USA Market Approval | USA |
| USA Designation Date | 2017-09-19 00:00:00 |
| Sponsor | Baxter Healthcare Corporation;32650 Wilson Road, WG1-3;Round Lake, Illinois, 60073 |
